Amarin Corporation plc (NASDAQ: AMRN) is making a run for the top in the market this morning, up more than 16% in the premarket. While the company hasn’t issued any news today, the gains seem to be a late reaction to positive news regarding the lifetime cost of Vascepa that was released yesterday. Here’s what’s going on:
AMRN Stock Is Climbing On Vascepa News
In a press release issued mid-day yesterday, Amarin Corporation announced a summary of results from a patient-level, cost-effectiveness analysis of Vascepa. In the release, the company said that the analysis evaluated the cost-effectiveness of the treatment in reducing cardiovascular risk among high risk patients.
AMRN said that the data show that Vascepa is projected to reduce long-term health care costs in a majority of scenarios analyzed. The cost analysis resulted in the following conclusion:
In this combined patient-level and simulation cost-effectiveness analysis, icosapent ethyl in high CV risk patients shows exceptional benefit with CV event reduction as well as cost-savings in-trial and over patients’ lifetime in the majority of simulations.
In a statement, John Thero, President and CEO at AMRN, had the following to offer:
This analysis helps to validate something we’ve long believed, and that is central to our mission. It is possible to deliver significant innovation that meaningfully addresses our nation’s most prevalent and costly health epidemic, reduces impacts on patients and families, and drives down costs longer term in the health system. We are working to make this therapy broadly available for improved patient care in high risk patients subject to appropriate regulatory review.
A Catalyst Is Just Days Away
When it comes to Amarin Corporation, there’s quite a bit for investors to be excited about. In fact, there are several positive catalysts on the horizon, with one just around the corner.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!